Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1.

HIV combination therapy broadly neutralizing antibody evolutionary biology evolutionary control human optimization physics of living systems population genetics stochastic processes viruses

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
19 07 2022
Historique:
received: 01 12 2021
accepted: 04 07 2022
pubmed: 20 7 2022
medline: 15 9 2022
entrez: 19 7 2022
Statut: epublish

Résumé

Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, we propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we predict the distribution of rebound times in three clinical trials. We show that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. Our results offer a rational therapy design for HIV, and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.

Identifiants

pubmed: 35852143
doi: 10.7554/eLife.76004
pii: 76004
pmc: PMC9467514
doi:
pii:

Substances chimiques

Antibodies, Neutralizing 0
Broadly Neutralizing Antibodies 0
HIV Antibodies 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2022, LaMont et al.

Déclaration de conflit d'intérêts

CL, JO, KV, HG, FK No competing interests declared, AN Reviewing editor, eLife

Références

JCI Insight. 2019 Sep 5;4(17):
pubmed: 31484826
Elife. 2019 Dec 10;8:
pubmed: 31820734
Retrovirology. 2018 Nov 16;15(1):73
pubmed: 30445968
J Clin Invest. 2005 Nov;115(11):3250-5
pubmed: 16276421
Science. 2016 May 20;352(6288):1001-4
pubmed: 27199430
IEEE Trans Pattern Anal Mach Intell. 1984 Jun;6(6):721-41
pubmed: 22499653
Science. 2004 Nov 26;306(5701):1547-50
pubmed: 15567861
Proc Natl Acad Sci U S A. 1981 Jan;78(1):454-8
pubmed: 6165991
PLoS Genet. 2020 Oct 21;16(10):e1009009
pubmed: 33085662
J Antimicrob Chemother. 2003 Feb;51(2):229-40
pubmed: 12562686
J Virol. 2015 Mar;89(5):2659-71
pubmed: 25520506
Cell. 2020 Feb 6;180(3):471-489.e22
pubmed: 32004464
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E564-E573
pubmed: 29311326
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
AIDS. 2001 Jun 15;15(9):F29-40
pubmed: 11416735
Nature. 2013 Apr 25;496(7446):441-2
pubmed: 23552894
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):
pubmed: 34301904
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7681-6
pubmed: 10884399
PLoS Pathog. 2020 Jun 3;16(6):e1008171
pubmed: 32492061
Nature. 2016 Jul 28;535(7613):556-60
pubmed: 27338952
Heredity (Edinb). 2008 Jan;100(1):19-31
pubmed: 17878920
Science. 2016 May 20;352(6288):997-1001
pubmed: 27199429
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16538-43
pubmed: 24043801
Vaccine. 2016 Oct 26;34(45):5442-5448
pubmed: 27622299
Mol Biol Evol. 2019 Oct 1;36(10):2184-2194
pubmed: 31209469
AIDS Rev. 2006 Jul-Sep;8(3):125-40
pubmed: 17078483
Nat Rev Immunol. 2013 Sep;13(9):693-701
pubmed: 23969737
J Virol. 2001 Nov;75(22):10892-905
pubmed: 11602729
Cell. 2015 Jun 4;161(6):1280-92
pubmed: 26004070
Curr Opin Virol. 2019 Oct;38:21-30
pubmed: 31132749
Immunol Rev. 2017 Jan;275(1):313-323
pubmed: 28133794
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
Genetics. 1988 Apr;118(4):705-11
pubmed: 17246421
Immunity. 2019 Feb 19;50(2):520-532.e3
pubmed: 30709739
PLoS Comput Biol. 2020 Feb 21;16(2):e1007626
pubmed: 32084132
PLoS Genet. 2016 Jul 21;12(7):e1006171
pubmed: 27442127
Elife. 2018 Mar 28;7:
pubmed: 29590010
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
Bioinformatics. 2001 May;17(5):415-8
pubmed: 11331235
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Immunity. 2013 Mar 21;38(3):606-17
pubmed: 23521886
AIDS. 2007 Mar 30;21(6):776-7
pubmed: 17413704
Bioessays. 2013 Jun;35(6):544-52
pubmed: 23613347
PLoS Comput Biol. 2022 Apr 6;18(4):e1010003
pubmed: 35385469
AIDS. 1999 Jul 30;13(11):F79-86
pubmed: 10449278
Science. 2012 Jul 13;337(6091):183-6
pubmed: 22798606
PLoS Comput Biol. 2020 Nov 30;16(11):e1008434
pubmed: 33253162
Curr Opin HIV AIDS. 2016 Jul;11(4):362-70
pubmed: 27259045
N Engl J Med. 2016 Nov 24;375(21):2019-2021
pubmed: 27959740
N Engl J Med. 2016 Nov 24;375(21):2037-2050
pubmed: 27959728
PLoS Pathog. 2017 May 25;13(5):e1006358
pubmed: 28542550
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):269-276
pubmed: 30211778
J Virol. 2017 Jul 27;91(16):
pubmed: 28539448
Science. 1996 Mar 15;271(5255):1582-6
pubmed: 8599114
Sci Transl Med. 2010 May 5;2(30):30ra32
pubmed: 20445200
Nature. 2013 Nov 14;503(7475):277-80
pubmed: 24172896
Elife. 2015 Dec 11;4:
pubmed: 26652000
Nat Med. 2021 Oct;27(10):1718-1724
pubmed: 34621054
PLoS Pathog. 2016 Mar 30;12(3):e1005520
pubmed: 27028935
Genet Res. 1966 Dec;8(3):269-94
pubmed: 5980116
Genetics. 2012 Oct;192(2):671-82
pubmed: 22851649
PLoS Pathog. 2011 Feb;7(2):e1001303
pubmed: 21383975
PLoS Genet. 2018 Jun 28;14(6):e1007420
pubmed: 29953449
Curr Opin Virol. 2012 Apr;2(2):134-41
pubmed: 22482710
Curr Opin HIV AIDS. 2017 May;12(3):229-240
pubmed: 28422787
J Bioinform Comput Biol. 2005 Feb;3(1):157-68
pubmed: 15751118
PLoS Comput Biol. 2010 Jan 29;6(1):e1000660
pubmed: 20126527
Science. 2013 Sep 13;341(6151):1199-204
pubmed: 24031012
J Virol. 2015 Apr;89(8):4201-13
pubmed: 25631091
Nat Rev Immunol. 2002 Jan;2(1):28-36
pubmed: 11905835
PLoS Pathog. 2018 Aug 20;14(8):e1007238
pubmed: 30125330
Front Immunol. 2021 Aug 31;12:710012
pubmed: 34531859
PLoS Pathog. 2018 Nov 5;14(11):e1007431
pubmed: 30395637
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Cell Host Microbe. 2017 Jun 14;21(6):777-787.e4
pubmed: 28579254
PLoS Genet. 2021 Jan 14;17(1):e1009050
pubmed: 33444376
Virus Evol. 2017 Mar 02;3(1):vex003
pubmed: 28458914
Elife. 2016 Feb 15;5:
pubmed: 26882502
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
J Virol. 2016 Jun 10;90(13):5899-5914
pubmed: 27053554
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
Science. 2009 Nov 20;326(5956):1123-7
pubmed: 19965434
Nat Immunol. 2018 Nov;19(11):1179-1188
pubmed: 30333615
AIDS. 2000 Jul 28;14(11):1481-8
pubmed: 10983634
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Cell. 2014 Feb 13;156(4):633-48
pubmed: 24529371
J Clin Invest. 2020 Apr 1;130(4):1699-1712
pubmed: 31910162
Bull Math Biol. 2007 Aug;69(6):2027-60
pubmed: 17450401
J Infect Dis. 2012 May 15;205 Suppl 2:S241-9
pubmed: 22448022
Nature. 2012 Dec 6;492(7427):118-22
pubmed: 23103874

Auteurs

Colin LaMont (C)

Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.

Jakub Otwinowski (J)

Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.

Kanika Vanshylla (K)

Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Henning Gruell (H)

Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Florian Klein (F)

Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Armita Nourmohammad (A)

Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.
Department of Physics, University of Washington, Seattle, United States.
Fred Hutchinson Cancer Research Center, Seattle, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH